Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of ops
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India.
RSS News
Economic times
0 thoughts on “Homegrown cell, gene therapy pioneer ImmunoACT turns profitable in first year of ops”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- Shah Rukh Khan Vs Salman Khan: One King, the other Sultan, both superstars, know who is more rich between Salman and Shah Rukh
- 'Reason he can't stand up to Trump is ...': Rahul's fresh charge at PM; claims 'Modi's hands are tied'
- Parliament logjam over SIR: Congress says discussion on 'votebandi' non-negotiable; asks why ignore Dhankar's 2023 ruling?
- Why is India buying so much war equipment worth Rs 67,000 crore? Missiles, aircraft, drones, and more
- 'Will call PM Modi': Brazil's Lula snubs Trump amid tariff row; rejects offer to reach out
